A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II pediatric dose-ranging study that will evaluate the safety,
tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in
patients <18 years of age who have relapsed or refractory acute leukemias that may benefit
from administration of midostaurin, including MLL-rearranged ALL and FLT3 positive AML.